A Faster Way to Detect Dangerous Synthetic Cannabinoids in Vape Liquids

Applied an in vitro CB1/β-arrestin2 recruitment assay (NanoBiT principle) to screen e-liquids for cannabinoid activity. Tested one e-liquid from an intoxicated patient and 23 commercially available e-liquids. Compared activity-based results with traditional analytical detection methods.

Synthetic cannabinoids in vape products are a growing public health problem, and detection methods can't keep up with the pace of new compound introduction. Activity-based screening detects what a substance does (activates cannabinoid receptors) rather than what it looks like chemically — meaning it can catch novel compounds that traditional analytical methods would miss. This could transform how quickly public health authorities identify dangerous products.

This detection technology addresses a gap identified in the semi-synthetic cannabinoid review (RTHC-00234) and connects to the synthetic cannabinoid potency testing (RTHC-00277). Those studies showed that new compounds emerge faster than they can be structurally identified; this assay sidesteps that problem by measuring biological activity directly. The finding that some CBD-labeled products contained hidden cannabinoid activity echoes the product quality concerns raised across multiple studies.

The assay detects CB1 receptor activity but cannot identify the specific compound responsible. It may not detect compounds that act through non-CB1 mechanisms. The 23-product sample is small and may not represent the full e-liquid market. The method requires laboratory equipment and cannot be used as a point-of-care test. False positives from naturally occurring cannabinoids in hemp-derived products need to be considered.